Granules India inaugurated water tank at Bonthapally village

The two overhead tanks commissioned at a cost of Rs 57 lakh will be maintained by the village panchayats.

Indian medical devices industry to grow at 28% annually to reach US$ 50 bn by 2030: Health Minister

Department and Industry Associations to organize 3 days National Level Expo on Indian Medical Devices Sector at Pragati Maidan, New Delhi between 9-11 Dec 2022, first of its kind expo in India

Dr VK Paul delivers lecture at NITI Aayog’s First India Development Strategies Lecture Series

Ours is a story of India’s resilient public health system and of everyone working together as team India to battle the pandemic

LISSUN raises ~$1 million in pre-Seed round from IvyCap Ventures and others

Funds raised will be used to develop technology and foster healthcare partnerships

Hester planning capacity expansion for Goat Pox vaccine

Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine

Novartis unveils new focused strategy

Transformation to pure-play Innovative Medicines company nears completion

CellOrigin Biotech collaborates with Qilu Pharma to develop CAR-iMAC Cell Therapy

JB Pharma rolls out its campaign #Heart2HeartChallengeIndia

The #Heart2HeartChallengeIndia campaign is very simple – you have to climb 60 steps in a minute, make a video of it, share it on your social media, tag 5 people, inviting them to take this challenge to check their heart health

Reasons for the surge in M& A in healthcare and pharmaceutical sectors in India: Ankit Poddar & Navroz Mahudawala, Candle Partners

Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.

Merck to initiate new Phase 3 clinical program for treatment of HIV-1 Infection

Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir